0001193125-25-323885.txt : 20251218 0001193125-25-323885.hdr.sgml : 20251218 20251218100627 ACCESSION NUMBER: 0001193125-25-323885 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20251218 DATE AS OF CHANGE: 20251218 EFFECTIVENESS DATE: 20251218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Virax Biolabs Group Ltd CENTRAL INDEX KEY: 0001885827 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-567275 FILM NUMBER: 251581607 BUSINESS ADDRESS: STREET 1: BIOCITY GLASGOW STREET 2: BO'NESS ROAD, NEWHOUSE CITY: LANARKSHIRE STATE: X0 ZIP: ML1 5UH BUSINESS PHONE: 44 020 7788 7414 MAIL ADDRESS: STREET 1: BIOCITY GLASGOW STREET 2: BO'NESS ROAD, NEWHOUSE CITY: LANARKSHIRE STATE: X0 ZIP: ML1 5UH FORMER COMPANY: FORMER CONFORMED NAME: Virax Biolabs (Cayman) Ltd DATE OF NAME CHANGE: 20210930 D 1 primary_doc.xml X0708 D LIVE 0001885827 Virax Biolabs Group Ltd BioCity Glasgow, Bo'Ness Road Newhouse Lanarkshire X0 UNITED KINGDOM ML1 SUH 44 020 7788 7414 CAYMAN ISLANDS None Virax Biolabs (Cayman) Ltd Corporation true 2021 James Foster Virax Biolabs Group Limited Bo'Ness Road Newhouse Lanarkshire X0 UNITED KINGDOM ML1 5UH Executive Officer Director Nigel McCracken Virax Biolabs Group Limited Bo'Ness Road Newhouse Lanarkshire X0 UNITED KINGDOM ML1 5UH Executive Officer Director Yair Erez Virax Biolabs Group Limited Bo'Ness Road Newhouse Lanarkshire X0 UNITED KINGDOM ML1 5UH Director Evan Norton Virax Biolabs Group Limited Bo'Ness Road Newhouse Lanarkshire X0 UNITED KINGDOM ML1 5UH Director Nelson Haight Virax Biolabs Group Limited Bo'Ness Road Newhouse Lanarkshire X0 UNITED KINGDOM ML1 5UH Director Biotechnology No Revenues 06b false 2025-12-03 false true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE 4TH FLOOR NEW YORK NY NEW YORK 10022 All States 5000000 5000000 0 The offering relates to the sale of unregistered warrants to purchase ordinary shares which are exercisable immediately after issuance. The above offering amount does not include the proceeds to be received by the Company upon exercise of such warrants. false 1 350000 0 The placement agent also received a management fee of $50,000, non-accountable expenses of $35,000, legal expenses of $50,000, and warrants to purchase up to 875,000 ordinary shares. 0 false Virax Biolabs Group Limited /s/ James Foster James Foster Chief Executive Officer 2025-12-17